Sommaire

• • ·The evolution of dermatologic therapeutics: Current uses of etanercept in psoriasis and other dermatoses

    Page :A1

    Plan Plan
• • ·Table of contents

    Page :A3

    
• • ·Introduction

    Page :S65

    Mark Lebwohl, Elizabeth H.Z. Thompson

    
• • ·Innate and adaptive immunity and the pathophysiology of psoriasis

    Page :S67

    Anthony A. Gaspari

    Résumé Résumé Plan Plan  
• • ·A European perspective on the challenges of managing psoriasis

    Page :S81

    Rosita Saraceno, Christopher E.M. Griffiths

    Plan Plan
• • ·The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach

    Page :S85

    Kenneth B. Gordon, Eric M. Ruderman

    Résumé Résumé Plan Plan  
• • ·Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database

    Page :S92

    Alice B. Gottlieb, Craig L. Leonardi, Bernard S. Goffe, Jean-Paul Ortonne, Peter C.M. van der Kerkhof, Ralph Zitnik, Arline Nakanishi, Angelika Jahreis

    Résumé Résumé Plan Plan  
• • ·Efficacy of etanercept in an integrated multistudy database of patients with psoriasis

    Page :S101

    Kenneth Gordon, Neil Korman, Ellen Frankel, Huei Wang, Angelika Jahreis, Ralph Zitnik, Ting Chang

    Résumé Résumé Plan Plan  
• • ·Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial

    Page :S112

    Gerald G. Krueger, Boni Elewski, Kim Papp, Andrea Wang, Ralph Zitnik, Angelika Jahreis

    Résumé Résumé Plan Plan  
• • ·Case reports of etanercept in inflammatory dermatoses

    Page :S139

    Robert Norman, Robert G. Greenberg, J. Mark Jackson

    Résumé Résumé Plan Plan  
• • ·What have we learned in dermatology from the biologic therapies?

    Page :S143

    Brian J. Nickoloff, Seth R. Stevens

    Résumé Résumé Plan Plan  

• CASE LETTERS

  • ·Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept

    Page :S120

    Joshua A. Zeichner, Dana W.K. Stern, Mark Lebwohl

    Plan Plan  
  • ·Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept

    Page :S121

    Paul S. Yamauchi, Nicholas J. Lowe, Vivian Gindi

    Plan Plan
  • ·Treatment of recurrent Sweet’s syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept

    Page :S122

    Paul S. Yamauchi, Logan Turner, Nicholas J. Lowe, Vivian Gindi, J. Mark Jackson

    Plan Plan  
  • ·Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis

    Page :S126

    Douglas W. Kress

    Plan Plan
  • ·The treatment of pyoderma gangrenosum using etanercept

    Page :S128

    David B. Roy, Eugene T. Conte, David J. Cohen

    Plan Plan  
  • ·A novel therapeutic approach to erythema annulare centrifugum

    Page :S134

    John Minni, Robert Sarro

     
  • ·Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis

    Page :S135

    Paul S. Yamauchi, Nicholas J. Lowe

    Plan Plan